Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
24 authors.
Jinsuke Nishino *Children's Research Institute and the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0009-0007-9736-8678
Wenhuo Hu *Department of Pathology, Center of Excellence for Leukemia Studies, St. Jude Children's Research Hospital, Memphis, Tennessee.ORCID 0000-0002-8686-7160
Ashwin Kishtagari *Division of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0003-1149-4571
Caroline M BlackmanChildren's Research Institute and the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0009-0003-2555-3277
Adetola KassimDivision of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0484-5903
Naimisha MarneniDivision of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0009-0008-6237-9024
Abhisar V CherukuriDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0009-0002-9849-9307
Russell VittrupDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0009-0005-0837-719X
Fatma N KalkanDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-1053-1193
Rahul ShahDivision of Hematology/Oncology, Department of Internal Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0001-6187-4690
Chul AhnDepartment of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-2997-9203
Ang GaoDepartment of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-6530-8768
Abeer AhmedrabieDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0009-0004-7373-5806
Robert H CollinsDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-0313-2394
Amer M ZeidanSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut.ORCID 0000-0001-7017-8160
Aram BidikianSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut.ORCID 0000-0001-5856-5926
Lohith GowdaSection of Hematology, Department of Internal Medicine, Yale University School of Medicine and Yale Cancer Center, New Haven, Connecticut.ORCID 0009-0001-1726-9749
Brian C ShafferDepartment of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3433-9179
Yazan F MadanatDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-9573-2690
Zhiyu ZhaoChildren's Research Institute and the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0001-6308-6997
Stephen S ChungDivision of Hematology/Oncology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-1433-7419
Sean J MorrisonChildren's Research Institute and the Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.ORCID 0000-0003-1587-8329
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
UT Southwestern Medical Center Simmons Comprehensive Cancer CenterP30CA142543 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Kathryn Ann O'Donnell · 2010 to 2026
$53.7M
Regulation of Protein Synthesis in Leukemia Stem CellsR37CA273232 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI Stephen Shiu-Wah Chung · 2023 to 2026
$1.9M
The Metabolic Regulation of Hematopoietic Stem Cell FunctionR01DK118745 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MORRISON, SEAN J · 2019 to 2023
$1.8M
The metabolic regulation of hematopoietic stem cell functionR56DK118745 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MORRISON, SEAN J · 2018 to 2018
$100k
Howard Hughes Medical Institute (HHMI) noneNational Cancer Institute (NCI) R37CA273232National Institutes of Health (NIH) DK118745NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA142543NCI NIH HHS R37 CA273232NIDDK NIH HHS R01 DK118745NIDDK NIH HHS R56 DK118745U.S. Department of Defense (DOD) W81XWH-22-1-0857
6 · The paper itself
Abstract
Peripheral nerves promote mouse bone marrow regeneration by activating β2- and β3-adrenergic receptor signaling, raising the possibility that nonselective β-blockers could inhibit engraftment after hematopoietic cell transplants (HCT). We observed no effect of β-blockers on steady-state mouse hematopoiesis. However, mice treated with a nonselective β-blocker (carvedilol), but not a β1-selective inhibitor (metoprolol), exhibited impaired hematopoietic regeneration after syngeneic or allogeneic HCTs. At two institutions, patients who received nonselective, but not β1-selective, β-blockers after allogeneic HCT exhibited delayed platelet engraftment and reduced survival. This was particularly observed in patients who received posttransplant chemotherapy for graft-versus-host disease prophylaxis, which also accentuated the inhibitory effect of carvedilol on engraftment in mice. In patients who received autologous HCTs, nonselective β-blockers were associated with little or no delay in engraftment. The inhibitory effect of nonselective β-blockers after allogeneic HCT was overcome by transplanting larger doses of hematopoietic cells. Significance: Patients who receive allogeneic HCTs followed by posttransplant chemotherapy for graft-versus-host disease prophylaxis may be at risk of delayed engraftment and increased mortality if administered nonselective β-blockers after transplantation. Transient discontinuation of nonselective β-blockers or transitioning to β1-selective inhibitors after HCT may accelerate engraftment and improve clinical outcomes. See related commentary by Bhatia, p. 666.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Nonselective β-Adrenergic Receptor Inhibitors Impair Hematopoietic Regeneration in Mice and Humans after Hematopoietic Cell Transplants. · full record | Socratic